Diana R Quintero, MD

Program director, Cystic Fibrosis, Children's Hospital of Wisconsin
Associate professor, the Medical College of Wisconsin

Office Locations

8915 W. Connell Ave
Milwaukee, WI 53226
414-266-6730 (office)
(877) 607-5280 (appointment)


Best Doctors 2013After years of training and practicing as a pediatric pulmonologist, Dr. Quintero continues to be fascinated with all the new concepts she learns every day. However, her motivation goes beyond acquiring more knowledge. She enjoys what she does when she makes every effort to learn, understand and treat any condition that ultimately will make a difference in someone else’s life, especially if it’s a child.

Pediatric Pulmonology, Pediatrics
Areas of Interest
  • Asthma
  • Cystic fibrosis
  • General pulmonology
  • Pulmonary and sleep medicine
  • Tracheostomy/home ventilator

Education & Awards

  • 1993, Universidad Del Valle (Cali, Columbia), MD
  • 1999, University of Illinois (Chicago, IL)
  • 2002, Baylor College of Medicine (Houston, TX)
  • 2006 – Outstanding Teaching Attending for Medical Students, Pediatrics, Medical College of Wisconsin, Milwaukee WI
  • 2007-2008 - Best Doctors® in America
  • 2008-2009 - Best Doctors® in America
  • 2009 - MCW Outstanding Faculty Service Award
  • 2009 - Outstanding Medical Student Teacher Award
  • 2009-2010 - Best Doctors® in America
  • 2010 - Cystic Fibrosis Foundation CF Center Quality Award
  • 2011-1012 - Best Doctors® in America

Research & Publications

  • KaloBios KB001A-05 A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001 A in Subjects with Cystic Fibrosis Infected with Pseudomonas aeruginosa
  • GS-US-205-0170: CAT Study. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Subjects with Cystic Fibrosis.
  • 5-Year CF Registry Study: A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa (PA) Isolates from Patients with Cystic Fibrosis in the United States [AIR-CF5].
  • A 10-Year Prospective Observational Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with CREON®